Bloomington, Ind. — Cook Medical’s Zenith Alpha® 2 Thoracic Endovascular Graft (ZTA2) is now commercially available throughout the United States. ZTA2 is the first aortic device on the market that has evolved to accommodate CO2 flushing and has an approved flushing protocol. This new addition reflects Cook’s commitment to improve patient outcomes through relentless innovation.
Cook Medical’s Zenith Alpha Thoracic 2 Endovascular Graft
ZTA2 is the latest iteration of Cook’s original Zenith Alpha Thoracic, built on Cook’s proven Zenith graft system and deployment technology. It has the same durability that physicians have come to rely on from the original Zenith Alpha Thoracic product, now with enhanced features.
When physicians are performing thoracic endovascular aortic repair (TEVAR) procedures, there’s a risk of introducing air bubbles into the vascular system, which can lead to severe injury to the patient, including stroke and/or death. ZTA2 offers physicians the option to flush the device with either saline alone or saline and CO2. Flushing with CO2, which is denser than air, helps to displace any remaining air within the device and minimize air emboli.1
“Cook is committed to innovating and delivering products and services in the aortic space. The company is heavily investing in our aortic strategy, and we have more exciting advancements coming in the near future,” said Johnny LeBlanc, a product director in Cook Medical’s Vascular division. “With its unique indication for CO2 flushing, ZTA2 offers physicians more options for on-label procedures as part of Cook’s comprehensive portfolio of aortic products.”
In addition to CO2 flushing, ZTA2 also comes with the following advancements:
- Changes to the gray positioner provide access to flush residual air spaces in the introduction system
- Redesign of proximal diameter reducing suture improves conformability for larger sizes
- Redesign of the bottom cap system on distal component helps avoid distal stent release failure
Since ZTA2 received FDA approval, select physicians have received early access through pre-launch partnerships with Cook. We congratulated Dr. Fernando Fleischman, Dr. Sukgu Han and Dr. Alyssa Pyun at Keck Medicine of USC for performing the first global implant of ZTA2 in January 2025. We have also celebrated first implant milestones of ZTA2 in certain regions of the US.
To see how ZTA2 supports physicians or to order ZTA2 for your hospital or practice, learn more about our Zenith® Thoracic product portfolio or reach out to your local Cook representative.
About Cook Medical
At Cook Medical, we are passionate about making unique, quality medical devices and connecting with people to improve lives. Founded on inventing, manufacturing, and delivering medical devices, we provide healthcare professionals with the tools they need to help their patients return to living.
Our commitment to innovation involves bringing new products to market and keeping existing products relevant to a changing healthcare landscape. We believe in using our business to help people and communities thrive by creating inclusive, supportive, and healthy environments.
We are proud of our history of innovative firsts and the impact we have on patients and communities. With headquarters in Bloomington, Indiana, and manufacturing facilities and offices in various global locations, we challenge ourselves to maintain a global perspective while focusing on local impact.
Follow Cook Medical at CookMedical.com and on LinkedIn.
1 Company-held nonclinical testing.
News coverage of this announcement
Vascular Disease Management–Zenith Alpha Thoracic 2 Now Available in US; First Case Performed
Vascular News–Cook Medical announce first US patient treated with Zenith Alpha 2 endovascular graft
Interventional News–Cook Medical announce first US patient treated with Zenith Alpha 2 endovascular graft
Endovascular Today–Cook’s Zenith Alpha 2 Thoracic Endovascular Graft Launched in the United States